Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Exp Parasitol ; 122(2): 145-54, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19422069

RESUMEN

We demonstrate that the combination of sub-optimal doses of Sodium Antimony Gluconate (SAG) and the diperoxovanadate compound K[VO(O2)2(H2O)], also designated as PV6, is highly effective in combating experimental infection of BALB/c mice with antimony resistant (Sb(R)) Leishmania donovani (LD) as evident from the significant reduction in organ parasite burden where SAG is essentially ineffective. Interestingly, such treatment also allowed clonal expansion of antileishmanial T-cells coupled with robust surge of IFN-c and concomitant decrease in IL-10 production. The splenocytes from the treated animals generated significantly higher amounts of IFN-c inducible parasiticidal effector molecules like superoxide and nitric oxide as compared to the infected group. Our study indicates that the combination of sub-optimal doses of SAG and PV6 may be beneficial for the treatment of SAG resistant visceral leishmaniasis patients.


Asunto(s)
Gluconato de Sodio Antimonio/administración & dosificación , Antiprotozoarios/administración & dosificación , Leishmania donovani/efectos de los fármacos , Leishmaniasis Visceral/tratamiento farmacológico , Peróxidos/administración & dosificación , Vanadatos/administración & dosificación , Animales , Gluconato de Sodio Antimonio/toxicidad , Antiprotozoarios/química , Antiprotozoarios/toxicidad , Líquido Ascítico/citología , Líquido Ascítico/parasitología , Supervivencia Celular/efectos de los fármacos , Cricetinae , Combinación de Medicamentos , Resistencia a Medicamentos , Interferón gamma/biosíntesis , Interferón gamma/efectos de los fármacos , Interleucina-10/biosíntesis , Leishmania donovani/inmunología , Leishmaniasis Visceral/inmunología , Leishmaniasis Visceral/parasitología , Hígado/parasitología , Mesocricetus , Ratones , Ratones Endogámicos BALB C , Óxido Nítrico/biosíntesis , Peróxidos/química , Peróxidos/toxicidad , Bazo/parasitología , Superóxidos/metabolismo , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , Vanadatos/química , Vanadatos/toxicidad
2.
Infect Immun ; 77(6): 2330-42, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19289510

RESUMEN

The membrane fluidity of antigen-presenting cells (APCs) has a significant bearing on T-cell-stimulating ability and is dependent on the cholesterol content of the membrane. The relationship, if any, between membrane fluidity and defective cell-mediated immunity in visceral leishmaniasis has been investigated. Systemic administration of cholesterol by liposome delivery (cholesterol liposomes) in Leishmania donovani-infected hamsters was found to cure the infection. Splenic macrophages as a prototype of APCs in infected hamsters had decreased membrane cholesterol and an inability to drive T cells, which was corrected by cholesterol liposome treatment. The effect was cholesterol specific because liposomes made up of the analogue 4-cholesten-3-one provided almost no protection. Infection led to increases in interleukin-10 (IL-10), transforming growth factor beta, and IL-4 signals and concomitant decreases in gamma interferon (IFN-gamma), tumor necrosis factor alpha, and inducible NO synthase signals, which reverted upon cholesterol liposome treatment. The antileishmanial T-cell repertoire, whose expansion appeared to be associated with protection, was presumably type Th1, as shown by enhanced IFN-gamma signals and the predominance of the immunoglobulin G2 isotype. The protected group produced significantly more reactive oxygen species and NO than the infected groups, which culminated in killing of L. donovani parasites. Therefore, cholesterol liposome treatment may be yet another simple strategy to enhance the cell-mediated immune response to L. donovani infection. To our knowledge, this is the first report on the therapeutic effect of cholesterol liposomes in any form of the disease.


Asunto(s)
Células Presentadoras de Antígenos/inmunología , Leishmania/inmunología , Leishmaniasis Visceral/tratamiento farmacológico , Leishmaniasis Visceral/inmunología , Fluidez de la Membrana/efectos de los fármacos , Animales , Membrana Celular/química , Colesterol/análisis , Colesterol/uso terapéutico , Cricetinae , Citocinas/metabolismo , Liposomas/uso terapéutico , Macrófagos/química , Macrófagos/inmunología , Óxido Nítrico/inmunología , Óxido Nítrico/metabolismo , Especies Reactivas de Oxígeno/inmunología , Especies Reactivas de Oxígeno/metabolismo
3.
Antimicrob Agents Chemother ; 50(5): 1788-97, 2006 May.
Artículo en Inglés | MEDLINE | ID: mdl-16641451

RESUMEN

Pentavalent antimony complexes, such as sodium stibogluconate and sodium antimony gluconate (SAG), are still the first choice for chemotherapy against various forms of leishmaniasis, including visceral leishmaniasis, or kala-azar. Although the requirement of a somewhat functional immune system for the antileishmanial action of antimony was reported previously, the cellular and molecular mechanism of action of SAG was not clear. Herein, we show that SAG induces extracellular signal-regulated kinase 1 (ERK-1) and ERK-2 phosphorylation through phosphoinositide 3-kinase (PI3K), protein kinase C, and Ras activation and p38 mitogen-activated protein kinase (MAPK) phosphorylation through PI3K and Akt activation. ERK-1 and ERK-2 activation results in an increase in the production of reactive oxygen species (ROS) 3 to 6 h after SAG treatment, while p38 MAPK activation and subsequent tumor necrosis factor alpha release result in the production of nitric oxide (NO) 24 h after SAG treatment. Thus, this study has provided the first evidence that SAG treatment induces activation of some important components of the intracellular signaling pathway, which results in an early wave of ROS-dependent parasite killing and a stronger late wave of NO-dependent parasite killing. This opens up the possibility of this metalloid chelate being used in the treatment of various diseases either alone or in combination with other drugs and vaccines.


Asunto(s)
Gluconato de Sodio Antimonio/farmacología , Leishmania donovani/inmunología , Macrófagos Peritoneales/inmunología , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Óxido Nítrico Sintasa de Tipo II/análisis , Fosfatidilinositol 3-Quinasas/metabolismo , Especies Reactivas de Oxígeno/análisis , Animales , Citocinas/análisis , Activación Enzimática/efectos de los fármacos , Homocigoto , Macrófagos Peritoneales/parasitología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Noqueados
4.
J Immunol ; 175(5): 3214-24, 2005 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-16116212

RESUMEN

Leishmania donovani-infected splenic macrophages and P388D1 (P388D1(I)) failed to activate T cells in response to low dose of exogenous peptide. The membrane fluidity of P388D1(I) was greater than that of the normal counterpart P388D1(N), but could be reduced either by exposing the cell below phase transition point or by loading cholesterol into membrane (L-P388D1(I)), and this was associated with enhanced Ag-presenting ability of P388D1(I). Presentation of endogenous leishmanial Ag, kinetoplastid membrane protein-11, was also defective, but could be corrected by loading cholesterol into membrane. Because membrane rafts are important for Ag presentation at a low peptide dose, raft architecture of P388D1(I) was studied using raft (CD48 and cholera toxin-B) and non-raft (CD71) markers in terms of their colocalization with I-A(d). Binding of anti-CD48 mAb and cholera toxin B subunit decreased significantly in P388D1(I), and consequently, colocalization with I-A(d) was not seen, but this could be restored in L-P388D1(I). Conversely, colocalization between I-A(d) and CD71 remained unaffected regardless of the presence or the absence of intracellular parasites. P388D1(N) and L-P388D1(I), but not P388D1(I), formed peptide-dependent synapse with T cells quite efficiently and this was found to be corroborated with both intracellular Ca2+ mobilization in T cells and IL-2 production. This indicated that intracellular parasites disrupt the membrane rafts, possibly by increasing the membrane fluidity, which could be corrected by making the membrane rigid. This may be a strategy that intracellular L. donovani adopts to evade host immune system.


Asunto(s)
Presentación de Antígeno , Leishmania donovani/inmunología , Macrófagos/inmunología , Microdominios de Membrana/fisiología , Animales , Células Presentadoras de Antígenos/inmunología , Antígenos CD/fisiología , Antígenos de Protozoos/metabolismo , Antígeno CD48 , Calcio/metabolismo , Línea Celular , Toxina del Cólera/farmacología , Colesterol/metabolismo , Antígenos de Histocompatibilidad Clase II/análisis , Macrófagos/parasitología , Fluidez de la Membrana , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos CBA , Linfocitos T/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA